Arlington Trust’s Corcept Therapeutics CORT Stock Holding History

Arlington Trust’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-43	Closed	-$1.4K	–	571
2023 Q4	$1.4K	Buy	+43	New	+$1.18K	﹤0.01%	744

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Arlington Trust's CORT Position: Q1 2024 in Review

Arlington Trust sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 43 shares — an estimated $1.4K sold.

Arlington Trust first reported a position in CORT in Q4 2023 and held it in 1 quarter. The position peaked at $1.4K in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

Arlington Trust reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 43 Corcept Therapeutics shares in Q1 2024, an estimated $1.4K.
Arlington Trust first reported a position in Corcept Therapeutics in Q4 2023 and held it in 1 quarter.
Arlington Trust's Corcept Therapeutics position peaked at $1.4K in Q4 2023.
287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.